Natera Inc NTRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Signatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer
-
Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™
-
ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology
-
Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026
-
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
-
FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay
-
Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma
-
New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
Trading Information
- Previous Close Price
- $404.90
- Day Range
- $401.00–415.00
- 52-Week Range
- $181.00–437.41
- Bid/Ask
- $403.00 / $437.25
- Shares Outstanding
- 144.14M
- Market Cap
- $59.22B
- Volume/Avg
- 186 / 1M
Key Statistics
- Price/Earnings (Normalized)
- 569.54
- Price/Sales
- 21.26
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 6,140
- Website
- https://www.natera.com
Valuation
|
Metric
|
NTRA
|
|---|---|
Price/Earnings (Normalized) | 569.54 |
Price/Book Value | 32.39 |
Price/Sales | 21.26 |
Price/Cash Flow | 206.24 |
Price/Earnings
NTRA
Financial Strength
|
Metric
|
NTRA
|
|---|---|
Quick Ratio | 2.74 |
Current Ratio | 3.00 |
Interest Coverage | −75.87 |
Quick Ratio
NTRA
Profitability
|
Metric
|
NTRA
|
|---|---|
Return on Assets (Normalized) | 4.35% |
Return on Equity (Normalized) | 6.27% |
Return on Invested Capital (Normalized) | 3.92% |
Return on Assets
NTRA
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|Wx#k!?n^ | LOCK|^C | $256B | |||
| Danaher Corp
DHR
| LOCK|ft!^LX$ | LOCK|qS$ | $163B | |||
| Agilent Technologies Inc
A
| LOCK|^#Q&j%!@ | LOCK|%p^ | $50B | |||
| Waters Corp
WAT
| LOCK|v$YGdX | LOCK|rW | $46B | |||
| IQVIA Holdings Inc
IQV
| LOCK|SGB^tc^ | LOCK|!>&g | $45B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|!Y>dTcF | LOCK|#qQ | $44B | |||
| Illumina Inc
ILMN
| LOCK|?&<J<&? | LOCK|$%>W | $42B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|nW#bqVf# | LOCK|<z>! | $34B | |||
| Labcorp Holdings Inc
LH
| LOCK|<>?f@jD | LOCK|<F#F& | $27B | |||
| Quest Diagnostics Inc
DGX
| LOCK|nKPCJ#r | LOCK|yvGT | $27B |
United States